nDatalyze Corp. (NDAT.CN)

CAD 0.03

(0.0%)

EBITDA Summary of nDatalyze Corp.

  • nDatalyze Corp.'s latest annual EBITDA in 2023 was -290.5 Thousand CAD , up 74.4% from previous year.
  • nDatalyze Corp.'s latest quarterly EBITDA in 2024 Q1 was -205.33 Thousand CAD , down -35.44% from previous quarter.
  • nDatalyze Corp. reported an annual EBITDA of -1.22 Million CAD in 2022, down -5.25% from previous year.
  • nDatalyze Corp. reported an annual EBITDA of -1.16 Million CAD in 2021, down -70.36% from previous year.
  • nDatalyze Corp. reported a quarterly EBITDA of -201.01 Thousand CAD for 2024 Q2, down -0.57% from previous quarter.
  • nDatalyze Corp. reported a quarterly EBITDA of 154.67 Thousand CAD for 2023 Q2, up 394.7% from previous quarter.

Annual EBITDA Chart of nDatalyze Corp. (2023 - 2017)

Historical Annual EBITDA of nDatalyze Corp. (2023 - 2017)

Year EBITDA EBITDA Growth
2023 -290.5 Thousand CAD 74.4%
2022 -1.22 Million CAD -5.25%
2021 -1.16 Million CAD -70.36%
2020 -688.5 Thousand CAD -1562.01%
2019 -25.69 Thousand CAD 83.74%
2018 -253.42 Thousand CAD -14073.38%
2017 - CAD 0.0%

Peer EBITDA Comparison of nDatalyze Corp.

Name EBITDA EBITDA Difference
AI/ML Innovations Inc. -1.66 Million CAD 82.551%
Diagnamed Holdings Corp. -100.27 Thousand CAD -189.716%
Pangenomic Health Inc. -2.71 Million CAD 89.287%
Treatment.Com International Inc. -3.64 Million CAD 92.033%
Unidoc Health Corp. -2.18 Million CAD 86.692%